Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12912566 | 0.90 | TP53 (0.54) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL30847404 | 0.87 | MAPK1 (0.65) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL27112980 | 0.87 | MAPK1 (0.65) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL3006093 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL1104823 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL14499607 | 0.83 | PDE10A (0.51) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL13916684 | 0.83 | HTT (0.72) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL338245 | 0.83 | ESR1 (0.54) | ALDH1A1HTTMAPK1HSD17B10MEN1 | |
| SCHEMBL13816413 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL12912581 | 0.81 | SIRT2 (0.50) | ALDH1A1HTTMAPK1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | claimed |
| EP-2173721-B1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-28 | — | — | EP | claimed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| EP-1602648-B2 | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO (JP) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-112830897-B | Ureido-containing benzimidazole derivative and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021098671-A1 | UREIDO-CONTAINING BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 石家庄以岭药业股份有限公司 | 2021-05-27 | — | — | WO | disclosed |
| CN-112830897-A | Ureido-containing benzimidazole derivative and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| EP-2174932-A2 | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same | Idemitsu Kosan Co., Ltd. (JP) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20060147747-A1 | 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage | IDEMITSU KOSAN CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1602648-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | AZI2, NISCH, UQCRB | ALDH1A1 97/4885HTT 3225/4885MAPK1 3459/4885 |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | EHD1, HCN2, ODC1 | ALDH1A1 2185/4885HTT 2253/4885MAPK1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.